Phase Ia dose escalation of IBI318, a first-in-class bispecific anti-PD-1/PD-L1, in patients with advanced tumors.

被引：0
|
作者：
Xu, Rui-hua
Zhao, Hongyun
Wei, Xiao-Li
Zhang, Yang
Wang, Feng
Wang, Zhiqiang
Wang, Fenghua
Li, Yu-Hong
Zou, Ben-Yan
Zhu, Xiaomin
Yu, Wencheng
Zhou, Hui
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Med Oncol,State Key Lab Oncol South China, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Canc Ctr, Dept Med Oncol, Guangzhou, Peoples R China
[4] Innovent Biol Inc, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3062
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study
    Ruan, Dan-Yun
    Wei, Xiao-Li
    Liu, Fu-Rong
    Hu, Xi-Chun
    Zhang, Jian
    Ji, Dong-Mei
    Huang, Ding-Zhi
    Zhao, Yan-Qiu
    Pan, Hong-Min
    Liao, Wang-Jun
    Yang, Kun-Yu
    Xu, Nong
    Lu, Xiao-Xiao
    Chen, Yu-Ling
    Zhang, Wen
    Zhou, Hui
    Zhao, Hong-Yun
    Xu, Rui-Hua
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [2] A phase Ia/b study of TIM-3/PD-L1 bispecific antibody in patients with advanced solid tumors.
    Hellmann, Matthew David
    Shimizu, Toshio
    Doi, Toshihiko
    Hodi, F. Stephen
    Rottey, Sylvie
    Aftimos, Philippe Georges
    Liu, Zhuqing Tina
    de Mendizabal, Nieves Velez
    Szpurka, Anna M.
    Piao, Yongzhe
    Vangerow, Burkhard
    Gandhi, Leena
    Leow, Ching Ching
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Phase Ia/Ib dose-escalation study of IBI110 (anti-LAG-3 mAb) as a single agent and in combination with sintilimab (anti-PD-1 mAb) in patients (pts) with advanced solid tumors.
    Zhou, Cai
    He, Yayi
    Ren, Shengxiang
    Li, Wei
    Zhu, Jun
    Yu, Jia
    Wang, Lei
    Xiong, Anwen
    Xu, Nong
    Mao, Chenyu
    Pan, Beiqing
    Liu, Ying
    Zhou, Hui
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
    Sui, Xinbing
    Ma, Junhong
    Han, Weidong
    Wang, Xian
    Fang, Yong
    Li, Da
    Pan, Hongming
    Zhang, Li
    ONCOTARGET, 2015, 6 (23) : 19393 - 19404
  • [5] A phase 1 study of MEDI4736, an anti PD-L1 antibody, in patients with advanced solid tumors.
    Lutzky, Jose
    Antonia, Scott Joseph
    Blake-Haskins, Andy
    Li, Xia
    Robbins, Paul B.
    Shaiabl, Aiman M.
    Vasseill, Jim
    Ibrahim, Ramy A.
    Khleif, Samir
    Segal, Neil Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial
    Amita Patnaik
    Glen J. Weiss
    Drew W. Rasco
    Lisa Blaydorn
    Amy Mirabella
    Murali Beeram
    Wei Guo
    Sharon Lu
    Hadi Danaee
    Kristen McEachern
    Ellie Im
    Jasgit C. Sachdev
    Cancer Chemotherapy and Pharmacology, 2022, 89 : 93 - 103
  • [7] PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis
    Abdel-Rahman, Omar
    IMMUNOTHERAPY, 2016, 8 (09) : 1081 - 1090
  • [8] A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors
    Martorana, F.
    Colombo, I.
    Treglia, G.
    Gillessen, S.
    Stathis, A.
    CANCER TREATMENT REVIEWS, 2021, 101
  • [9] A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors
    Naing, Aung
    Gainor, Justin F.
    Gelderblom, Hans
    Forde, Patrick M.
    Butler, Marcus O.
    Lin, Chia-Chi
    Sharma, Sunil
    de Olza, Maria Ochoa
    Varga, Andrea
    Taylor, Matthew
    Schellens, Jan H. M.
    Wu, Hongqian
    Sun, Haiying
    Silva, Antonio P.
    Faris, Jason
    Mataraza, Jennifer
    Cameron, Scott
    Bauer, Todd M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [10] Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial
    Patnaik, Amita
    Weiss, Glen J.
    Rasco, Drew W.
    Blaydorn, Lisa
    Mirabella, Amy
    Beeram, Murali
    Guo, Wei
    Lu, Sharon
    Danaee, Hadi
    McEachern, Kristen
    Im, Ellie
    Sachdev, Jasgit C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (01) : 93 - 103
12345